Icatibanto Fresenius (Icatibant Acetate)

Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the swelling seen in hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The medication is administered as a single subcutaneous injection for each acute HAE episode, with repeat dosing only if medically indicated.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates act by replacing a deficient protein. Icatibant offers a rapid, subcutaneous route of administration and is particularly useful for patients who prefer self‑injection over intravenous therapy.

Icatibanto Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

The medication is given as a single subcutaneous injection into the abdominal wall or thigh. Healthcare professionals or trained patients can perform the injection using the supplied pre‑filled syringe, following aseptic technique and manufacturer instructions.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of thrombocytopenia. Patients should be monitored for signs of allergic response, sudden drops in blood pressure, or abnormal bleeding after administration.

Icatibanto Fresenius is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or other drugs that increase bradykinin levels, as the risk of angioedema may be heightened.